PT1028738E - Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas - Google Patents

Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas

Info

Publication number
PT1028738E
PT1028738E PT98957605T PT98957605T PT1028738E PT 1028738 E PT1028738 E PT 1028738E PT 98957605 T PT98957605 T PT 98957605T PT 98957605 T PT98957605 T PT 98957605T PT 1028738 E PT1028738 E PT 1028738E
Authority
PT
Portugal
Prior art keywords
mitogens
cytokines
inhibit pathological
immunity responses
pathological immunity
Prior art date
Application number
PT98957605T
Other languages
English (en)
Inventor
David A Horwitz
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of PT1028738E publication Critical patent/PT1028738E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT98957605T 1997-11-05 1998-11-05 Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas PT1028738E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6450797P 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
PT1028738E true PT1028738E (pt) 2003-08-29

Family

ID=22056456

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98957605T PT1028738E (pt) 1997-11-05 1998-11-05 Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas

Country Status (11)

Country Link
US (1) US6228359B1 (pt)
EP (1) EP1028738B1 (pt)
JP (1) JP4309047B2 (pt)
AT (1) ATE238061T1 (pt)
AU (1) AU747767B2 (pt)
CA (1) CA2309115C (pt)
DE (1) DE69813868T2 (pt)
DK (1) DK1028738T3 (pt)
ES (1) ES2198774T3 (pt)
PT (1) PT1028738E (pt)
WO (1) WO1999025366A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) * 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
CA2372956A1 (en) * 1999-05-05 2000-11-09 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
JP2003508047A (ja) * 1999-09-01 2003-03-04 ユニバーシティ・オブ・サザン・カリフォルニア 移植片−対−宿主疾患を抑制するサイトカイン、細胞およびマイトジェンの使用
AU2007202534B2 (en) * 2000-04-11 2011-06-09 University Of Southern California A method to prevent graft rejection using TGF-beta to induce T suppressor cells
CA2405806A1 (en) * 2000-04-11 2001-10-18 University Of Southern California A method to prevent graft rejection using tgf-.beta. to induce t suppressor cells
AU2002364230B2 (en) * 2001-12-21 2008-05-01 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8951796B2 (en) 2010-04-22 2015-02-10 University Of Southern California Methods and compositions for expanding and stabilizing natural regulatory T cells
WO2013050529A2 (en) 2011-10-06 2013-04-11 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
WO2013173076A1 (en) 2012-05-04 2013-11-21 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
DE69813868T2 (de) 2004-03-04
EP1028738B1 (en) 2003-04-23
DK1028738T3 (da) 2003-08-11
WO1999025366A1 (en) 1999-05-27
EP1028738A1 (en) 2000-08-23
JP4309047B2 (ja) 2009-08-05
AU747767B2 (en) 2002-05-23
ATE238061T1 (de) 2003-05-15
ES2198774T3 (es) 2004-02-01
US6228359B1 (en) 2001-05-08
JP2001523443A (ja) 2001-11-27
CA2309115C (en) 2010-10-19
DE69813868D1 (de) 2003-05-28
AU1382799A (en) 1999-06-07
CA2309115A1 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
PT1028738E (pt) Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas
DE69725153D1 (de) Kaliumkanal-blocker
ATE190357T1 (de) Schnelles verfahren fur die dns sequenzierung und diagnostische anwendungen
DE3676929D1 (de) Schwefelenthaltende zusammensetzung und konzentrate und schmieroele die diese enthalten.
IL143747A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
EA199800667A1 (ru) Новые фенантридины
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69014030T3 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
MX9303127A (es) Metodo para reducir selectivamente la poblacion celular de leucocitos.
WO2004006853A3 (en) Treatment and prophylaxis with 4-1bb-binding agents
DE69715442T2 (de) Fluorierte triallylisocyanurate, vulkanisierbare elastomerzusammensetzungen die diese enthalten, und vulkanisationsverfahren
NO881051D0 (no) Metoder for behandling av solskadet, human hud med retinoider.
DE3773649D1 (de) Behandlungsverfahren und system fuer bohrschlaemme und dergl.
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
FR2491334B1 (pt)
DE3782214D1 (de) Mittel zur behandlung des scheidenmilieus.
PT77019A (de) Mittel zur behandlung von wunden
BG101126A (en) The use of muramylpeptide compounds
KR910016342A (ko) 항원 용액을 위한 보조제로서의 아연, 칼슘 하이드록 사이드, 렉시틴 및 pao의 용도, 및 이러한 유형의 보조제로 처리된 항원 용액
DE69007374D1 (de) Injektionssystem für die Behandlung von Zellen.
PT1092040E (pt) Metodos de inibicao helicobacter pylori
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.